CDC42 and cancer: It is suggested that Cdc42 participates in anti-cancer drug resistance by interacting with N-WASP and Arp2/3 to promote actin polymerization, microfilament cytoskeleton rearrangement, intracellular material flow acceleration and promotion of intracellular drug excretion to the extracellular space.